Latest News

Biochemical recurrence (BCR) after primary treatment of localized prostate cancer does not necessarily lead to clinically apparent progressive disease. To aid in prognostication, the European Association of Urology prostate cancer guidelines panel undertook a systematic review and successfully developed a novel BCR risk stratification system (groups with a low risk or high risk of BCR) […]

Pilot Study of the Blockade of Androgens in Renal Cell Carcinoma Using Enzalutamide (BARE) Condition: Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer Intervention: Drug: Enzalutamide Other: Laboratory Biomarker Analysis Procedure: Nephrectomy Purpose: This pilot phase 0 trial studies how well enzalutamide works before surgery in treating patients with kidney cancer. Androgens are […]

A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) in Patients With Advanced Renal Cell Carcinoma in Second or Third Line Setting in Real Life Condition: Renal Cell Carcinoma, Renal Cell Cancer, Adenocarcinoma Of Kidney, Adenocarcinoma, Renal Cell, Kidney Cancer, Cancer of the Kidney Intervention: Other: Non-interventional Purpose: This is a French, nationwide, prospective, observational, […]

Phase II Trial of Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma (mRCC) Condition: Metastatic Clear Cell Renal Cell Carcinoma Intervention: Drug: Nivolumab Radiation: SAbR Purpose: Nivolumab (brand name Opdivo): IV, 3 mg/kg q2 weeks, until disease progression or unacceptable toxicity; SABR, dose variable, in 1-3 fractions. Study Type: […]

Evaluation of PSMA-based PET as an Imaging Biomarker of Androgen Receptor Signaling in High-Risk Localized and Locally Advanced Prostate Cancer Condition: Advanced Prostate Cancer Intervention: Drug: Pelvic DCFPyL PET-MRI fusion or PET/MRI Purpose: This research is being done to see if an investigational radioactive imaging agent (radiotracer) called 18F-DCFPyL can help us find prostate cancer […]

Pioglitazone and Risk of Bladder Cancer in Patients With Type 2 Diabetes Mellitus”PROBE-PIO”Study Condition: Bladder Cancer Intervention: Drug: Pioglitazone Purpose: Pioglitazone, an agonist of the peroxisome-proliferator-activated receptor (PPAR), is a relatively new oral anti-hyperglycemic drug. Since its first approval in the USA in 1999, a potential link with bladder cancer has been a subject of […]

Phase II Study of Adjuvant 3D-Conformal Radiotherapy in High Risk Bladder Cancer Condition: Bladder Cancer, Squamous Cell Carcinoma of the Bladder, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder Intervention: Radiation: 3D conformal radiation therapy Purpose: This phase II trial studies how well modern, conformal radiation therapy after surgery […]

Utilising Circulating Tumour Cell (CTC) Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer: CTC-STOP Trial Condition: Adenocarcinoma of the Prostate Intervention: Other: Active CTC Assessment Purpose: CTC-STOP is a multicentre prospective randomised controlled phase III trial for metastatic castration-resistant prostate cancer patients. This study will determine if serial CTC counts can be used as […]

San Francisco, CA (UroToday.com) — OncoCell MDx, an immunogenomics platform company specializing in the delivery of novel, noninvasive molecular diagnostic assays, announced the appointment of Christopher Thibodeau as its Chief Operating Officer. He joins Mark McDonough, recently appointed as OncoCell’s President, Chief Executive Officer and member of the Board of Directors, in strengthening the company’s […]

Charles Ryan: Hello. I am joined by Dr. Pamela Munster, my friend and colleague from the University of California, San Francisco, and most recently, an author, of the book Twisting Fate: My Journey with BRCA from Breast Cancer Doctor to Patient and Back. It’s a remarkable story. I really enjoyed reading it. I knew you, […]